ArticleAnnals of hematology2025
A multicenter study on the prognostic value of prednisone response in pediatric acute lymphoblastic leukemia.
Article in Annals of hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- CD71 as an independent prognostic factor in pediatric B-ALL: a regional multicenter retrospective study in Southern China (SCCLG-ALL-2016).Therapeutic advances in medical oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors.
Funding
Abstract
backgroundPrednisone response (PR) remains a key early treatment indicator in pediatric acute lymphoblastic leukemia (ALL). However, its independent prognostic significance has waned with the advent of minimal residual disease (MRD)-guided risk assessment. Evaluating the enduring biological and clinical significance of PR, especially in high-risk subtypes, could enhance the precision of therapeutic approaches.
methodsThis retrospective study analyzed clinical data from 2,979 pediatric patients primarily diagnosed with acute lymphoblastic leukemia (ALL) and enrolled in the South China Children's Leukemia Group (SCCLG-ALL)-2016 Collaborative Group between October 2016 and June 2023. Patients were categorized into "good prednisone response" (GPR) and "poor prednisone response" (PPR) groups based on their response to prednisone. Clinical characteristics were compared between groups using the chi-square test. Logistic regression was employed to analyze the correlation between prednisone response and early minimal residual disease (MRD). Survival analysis was performed using Kaplan-Meier curves, and prognostic factors were evaluated using Cox regression models.
resultsAmong the 2,979 patients, 2,649 were categorized as GPR and 330 as PPR. Children in the PPR group exhibited multiple high-risk clinical features and had a poorer prognosis than those in the GPR group. However, multivariate Cox regression analysis revealed that days 15 and 33 MRD had a stronger predictive value than prednisone response. Notably, PR showed strong predictive value for MRD positivity on both Day 15 and Day 33.
conclusionsIn this large real-world Chinese cohort, PR was not an independent prognostic marker but was strongly associated with early MRD burden. These findings support the contextual use of PR as a practical surrogate for MRD in resource-limited settings, and highlight the need to reconsider its role in modern risk-adapted treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.